ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

NCT03698552 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

37

Enrollment

OTHER

Sponsor class

Stopped \<75% participation

Conditions

Blasts 5 Percent or More of Bone Marrow Nucleated Cells
CD22 Positive
Philadelphia Chromosome Positive
Recurrent B Acute Lymphoblastic Leukemia
Refractory B Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL: ADCT-602

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]